A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia

International Journal of Neuropsychopharmacology

Volumn 8, Issue 3, 2005, Pages 457-472

  Woodward, Neil D ^a   Purdon, Scot E ^b   Meltzer, Herbert Y ^c   Zald, David H ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Atypical antipsychotics; Meta analysis; Neuropsychology; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

APTITUDE TEST; CALCULATION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVALUATION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DOMAIN; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOPHRENIA; STANDARD; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; VERBAL BEHAVIOR; VOCATIONAL REHABILITATION;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DIBENZOTHIAZEPINES; HUMANS; MEDLINE; NEUROPSYCHOLOGICAL TESTS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 21244448316     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S146114570500516X     Document Type: Review

References (97)

1. Bedard MA, Scherer H, Delorimier J, Stip E, Lalonde P (1996). Differential effects of D2- and D4-blocking neuroleptics on the procedural learning of schizophrenic patients. Canadian Journal of Psychiatry 41, S21-S24.
2. Bedard MA, Scherer H, Stip E, Cohen H, Rodriguez JP, Richer F (2000). Procedural learning in schizophrenia: further consideration on the deleterious effect of neuroleptics. Brain and Cognition 43, 31-39.
3. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, Pappadopulos E, Willson DF, Alvir JM, Woerner MG, Geisler S, Kane JM, Lieberman JA (2000). Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. American Journal of Psychiatry 157, 549-559.
4. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA (2002). Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. American Journal of Psychiatry 159, 1018-1028.
5. Bleuler E (1950). Dementia Praecox or, the Group of Schizophrenias. New York: International Universities Press.
6. Blyler CR, Gold JM (2000). Cognitive effects of conventional antipsychotics: another look. In: Sharma T, Harvey PD (Eds.), Cognitive Functioning in Schizophrenia: Characteristics, Correlates, and Treatment (pp. 241-265). Oxford, UK: Oxford University Press.
7. Buchanan RW, Holstein C, Breier A (1994). The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biological Psychiatry 36, 717-725.
8. Bymaster FP, Felder CC, Tzavara E, Nomikos GG, Calligaro DO, McKinzie DL (2003). Muscarinic mechanisms of antipsychotic atypicality. Progress in Neuropsychopharmacology & Biological Psychiatry 27, 1125-1143.
9. Carpenter WT, Gold JM (2002). Another view of therapy for cognition in schizophrenia. Biological Psychiatry 51, 969-971.
10. Chengappa KN, Pollock BG, Parepally H, Levine J, Kirshner MA, Brar JS, Zoretich RA (2000). Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. Journal of Clinical Psychopharmacology 20, 311-316.
11. Chua L, Chong SA, Pang E, Ng VP, Chan YH (2001). The effect of risperidone on cognitive functioning in a sample of Asian patients with schizophrenia in Singapore. Singapore Medical Journal 42, 243-246.
12. Cuesta MJ, Peralta V, Zarzuela A (2001). Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophrenia Research 48, 17-28.
13. Eschweiler GW, Bartels M, Langle G, Wild B, Gaertner I, Nickola M (2002). Heart-rate variability (HRV) in the ECG trace of routine EEGs: fast monitoring for the anticholinergic effects of clozapine and olanzapine? Pharmacopsychiatry 35, 96-100.
14. Felder CC, Porter AC, Skillman TL, Zhang L, Bymaster FP, Nathanson NM, Hamilton SE, Gomeza J, Wess J, McKinzie DL (2001). Elucidating the role of muscarinic receptors in psychosis. Life Sciences 68, 2605-2613.
15. Fleming K, Thyrum P, Yeh C, Vargo DL, Potkin SG (2001). Cognitive improvements in psychotic subjects treated with 'Seroquel' (quetiapine fumarate): an exploratory study. Journal of Clinical Psychopharmacology 21, 527-529.
16. Fujii DE, Ahmed I, Jokumsen M, Compton JM (1997). The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. Journal of Clinical Neuropsychiatry and Clinical Neuroscience 9, 240-245.
17. Fuller R, Nopoulos P, Arndt S, O'Leary D, Ho BC, Andreasen NC (2002). Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. American Journal of Psychiatry 159, 1183-1189.
18. Galletly CA, Clark CR, McFarlane AC, Weber DL (1997). Relationships between changes in symptom ratings, neurophysiological test performance and quality of life in schizophrenic patients treated with clozapine. Psychiatry Research 72, 161-166.
19. Galletly CA, Clark CR, McFarlane AC, Weber DL (1999). Effects of clozapine for non-treatment-resistant patients with schizophrenia. Psychiatric Services 50, 101-103.
20. Galletly CA, Clark CR, McFarlane AC, Weber DL (2000). The effect of clozapine on the speed and accuracy of information processing in schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 24, 1329-1338.
21. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, Schulz SC, Weinberger DR (1993). The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. British Journal of Psychiatry 162, 43-48.
22. Good KP, Kiss I, Buiteman C, Woodley H, Rui Q, Whitehorn D, Kopala L (2002). Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis. British Journal of Psychiatry (Suppl. 43), S45-S49.
23. Grace J, Bellus SB, Raulin ML, Herz MI, Priest BL, Brenner V, Donnelly K, Smith P, Gunn S (1996). Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning. Psychiatric Services 47, 41-45.
24. Green MF (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry 153, 321-330.
25. Green MF, Kern RS, Braff DL, Mintz J (2000). Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the 'right stuff'? Schizophrenia Bulletin 26, 119-136.
26. Green MF, Marder SR, Glynn SM, McGurk SR, Wirshing WC, Wirshing DA, Liberman RP, Mintz J (2002). The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biological Psychiatry 51, 972-978.
27. Green MF, Marshall Jr. BD, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J (1997). Does risperidone improve verbal working memory in treatment-resistant schizophrenia? American Journal of Psychiatry 154, 799-804.
28. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY (1993). Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry 34, 702-712.
29. Harvey PD, Green MF, McGurk SR, Meltzer HY (2003). Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berlin) 169, 404-411.
30. Harvey PD, Keefe RS (2001). Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. American Journal of Psychiatry 158, 176-184.
31. Harvey PD, Moriarty PJ, Serper MR, Schnur E, Lieber D (2000). Practice-related improvement in information processing with novel antipsychotic treatment. Schizophrenia Research 46, 139-148.
32. Harvey PD, Siu CO, Romano S (2004). Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology (Berlin) 172, 324-332.
33. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV (2001). Stability and course of neuropsychological deficits in schizophrenia. Archives of General Psychiatry 58, 24-32.
34. Hedges LV, Vevea JL (1998). Fixed- and random-effects models in meta-analysis. Psychological Methods 3, 486-504.
35. Heinrichs RW, Zakzanis KK (1998). Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12, 426-445.
36. Hoff AL, Faustman WO, Wieneke M, Espinoza S, Costa M, Wolkowitz O, Csernansky JG (1996). The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology 15, 361-369.
37. Hoff AL, Riordan H, O'Donnell DW, Morris L, DeLisi LE (1992). Neuropsychological functioning of first-episode schizophreniform patients. American Journal of Psychiatry 149, 898-903.
38. Hong KS, Kim JG, Koh HJ, Koo MS, Kim JH, Lee D, Kim E (2002). Effects of risperidone on information processing and attention in first-episode schizophrenia. Schizophrenia Research 53, 7-16.
39. Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY (2002). Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26, 325-339.
40. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY (2001). 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. Journal of Neurochemistry 76, 1521-1531.
41. Kapur S, Seeman P (2001). Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. American Journal of Psychiatry 158, 360-369.
42. Keefe RS, Roitman SE, Harvey PD, Blum CS, DuPre RL, Prieto DM, Davidson M, Davis KL (1995). A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophrenia Research 17, 25-33.
43. Keefe RS, Silva SG, Perkins DO, Lieberman JA (1999). The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophrenia Bulletin 25, 201-222.
44. Keefe RSE, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RRJ, Yurgelin-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA, and the HGDH Research Group (2004). Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first episode psychosis: a randomized, double blind trial of olanzapine versus haloperidol. American Journal of Psychiatry 161, 985-995.
45. Kennedy JS, Zagar A, Bymaster F, Nomikos G, Trzepacz PT, Gilmore JA, Rotelli MD, Breier A, Tollefson G (2001). The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease. International Journal of Geriatric Psychiatry 16 (Suppl. 1), S24-S32.
46. Kern RS, Green MF, Marshall Jr. BD, Wirshing WC, Wirshing D, McGurk S, Marder SR, Mintz J (1998). Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. Biological Psychiatry 44, 726-732.
47. Kern RS, Green MF, Marshall Jr. BD, Wirshing WC, Wirshing D, McGurk SR, Marder SR, Mintz J (1999). Risperidone versus haloperidol on secondary memory: can newer medications aid learning? Schizophrenia Bulletin 25, 223-232.
48. Kolb B, Whishaw IQ (1983). Performance of schizophrenic patients on tests sensitive to left or right frontal, temporal, or parietal function in neurological patients. Journal of Nervous Disease and Mental Disorder 171, 435-443.
49. Kraepelin E, Robertson GM (1919). Dementia Praecox and Paraphrenia. Edinburgh: Livingstone.
50. Kuroki T, Meltzer HY, Ichikawa J (1999). Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. Journal of Pharmacology and Experimental Therapeutics 288, 774-781.
51. Lavalaye J, Linszen DH, Booij J, Reneman L, Gersons BP, van Royen EA (1999). Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia. Psychiatry Research 92, 33-44.
52. Lee MA, Jayathilake K, Meltzer HY (1999). A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophrenia Research 37, 1-11.
53. Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 35, 51-68.
54. Lindenmayer JP, Iskander A, Park M, Apergi FS, Czobor P, Smith R, Allen D (1998). Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. Journal of Clinical Psychiatry 59, 521-527.
55. Liu SK, Chen WJ, Chang CJ, Lin HN (2000). Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol. Neuropsychopharmacology 22, 311-319.
56. Ljubin T, Zakic MD, Mimica N, Folnegovic-Smalc V, Makaric G (2000). A preliminary study of the comparative effects of olanzapine and fluphenazine on cognition in schizophrenic patients. Human Psychopharmacology 15, 513-519.
57. Manschreck TC, Redmond DA, Candela SF, Maher BA (1999). Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia. Journal of Clinical Neuropsychiatry and Clinical Neuroscience 11, 481-489.
58. McGurk S, Green MF, Wirshing WC, Ames DC, Marshall Jr. BD, Marder SR, Mintz JM (1997). The effects of risperidone vs. haloperidol on cognitive functioning in treatment-resistant schizophrenia: the trial making test. CNS Spectrums 2, 60-64.
59. McGurk S, Powchick P (2000). The central cholinergic system and cognitive dysfunction in schizophrenia. In: Sharma T, Harvey PD (Eds.), Cognitive Functioning in Schizophrenia: Characteristics, Correlates, and Treatment. Oxford, UK: Oxford University Press.
60. Meltzer HY (1999). The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21, 106S-115S.
61. Meltzer HY, McGurk SR (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 25, 233-255.
62. Olianas MC, Maullu C, Onali P (1999). Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells. Neuropsychopharmacology 20, 263-270.
63. Olincy A, Young DA, Freedman R (1997). Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biological Psychiatry 42, 1-5.
64. Parada MA, Hernandez L, Puig DP, Rada P, Murzi E (1997). Selective action of acute systemic clozapine on acetylcholine release in the rat prefrontal cortex by reference to the nucleus accumbens and striatum. Journal of Pharmacology and Experimental Therapeutics 281, 582-588.
65. Potkin SG, Fleming K, Jin Y, Gulasekaram B (2001). Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. Journal of Clinical Psychopharmacology 21, 479-483.
66. Purdon SE (1999). Cognitive improvement in schizophrenia with novel antipsychotic medications. Schizophrenia Research 35 (Suppl), S51-S60.
67. Purdon SE (2000). Measuring neuropsychological change in schizophrenia with novel antipsychotic medications. Journal of Psychiatry and Neuroscience 25, 108-116.
68. Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Breier A, Tollefson GD (2000). Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Archives of General Psychiatry 57, 249-258.
69. Purdon SE, Labelle A, Boulay L (2001a). Neuropsychological change in schizophrenia after 6 weeks of clozapine. Schizophrenia Research 48, 57-67.
70. Purdon SE, Malla A, Labelle A, Lit W (2001b). Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. Journal of Psychiatry and Neuroscience 26, 137-149.
71. Purdon SE, Woodward N, Lindborg SR, Stip E (2003). Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol. Psychopharmacology (Berlin) 169, 390-397.
72. Purdon SE, Woodward ND, Mintz A, Labelle A (2002). Procedural learning improvements after six weeks of clozapine treatment. Schizophrenia Research 53, 165-166.
73. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V (2003). Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. Journal of the American Medical Association 290, 2693-2702.
74. Rosenthal R (1994). Parametric measures of effect size. In: Cooper HM, Hedges LV (Eds.), The Handbook of Research Synthesis (pp. 231-244). New York: Russell Sage Foundation.
75. Rossi A, Mancini F, Stratta P, Mattei P, Gismondi R, Pozzi F, Casacchia M (1997). Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatrica Scandinavica 95, 40-43.
76. Rybakowski JK, Borkowska A (2001). The effect of treatment with risperidone, olanzapine, or phenothiazines on cognitive functions in patients with schizophrenia. International Journal of Psychiatry in Clinical Practice 5, 249-256.
77. Sax KW, Strakowski SM, Keck Jr. PE (1998). Attentional improvement following quetiapine fumarate treatment in schizophrenia. Schizophrenia Research 33, 151-155.
78. Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, Gur RC (1994). Neuropsychological deficits in neuroleptic naive patients with first- episode schizophrenia. Archives of General Psychiatry 51, 124-131.
79. Schall U, Catts SV, Chaturvedi S, Liebert B, Redenbach J, Karayanidis F, Ward PB (1998). The effect of clozapine therapy on frontal lobe dysfunction in schizophrenia: neuropsychology and event-related potential measures. International Journal of Neuropsychopharmcology 1, 19-29.
80. Schotte A, Janssen PF, Bonaventure P, Leysen JE (1996). Endogenous dopamine limits the binding of antipsychotic drugs to D3 receptors in the rat brain: a quantitative autoradiographic study. Histochemical Journal 28, 791-799.
81. Seeman P (2002). Atypical antipsychotics: mechanism of action. Canadian Journal of Psychiatry 47, 27-38.
82. Shadish WR, Haddock CK (1994). Combining estimates of effect size. In: Cooper HM, Hedges LV (Eds.), The Handbook of Research Synthesis (pp. 261-282). New York: Russell Sage Foundation.
83. Sharma T, Harvey PD (2000). Cognition in Schizophrenia Impairments, Importance, and Treatment Strategies. Oxford, UK: Oxford University Press.
84. Sharma T, Hughes C, Soni W, Kumari V (2003). Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. Psychopharmacology (Berlin) 169, 398-403.
85. Shirazi-Southall S, Rodriguez DE, Nomikos GG (2002). Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26, 583-594.
86. Simosky JK, Stevens KE, Adler LE, Freedman R (2003). Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology (Berlin) 165, 386-396.
87. Smith ML, Glass GV, Miller TI (1980). The Benefits of Psychotherapy. Baltimore: Johns Hopkins University Press.
88. Smith RC, Infante M, Singh A, Khandat A (2001). The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. International Journal of Neuropsychopharmacology 4, 239-250.
89. Spreen O, Strauss E (1998). A Compendium of Neuropsychological Tests Administration, Norms, and Commentary. New York: Oxford University Press.
90. Stevens A, Schwarz J, Schwarz B, Ruf I, Kolter T, Czekalla J (2002). Implicit and explicit learning in schizophrenics treated with olanzapine and with classic neuroleptics. Psychopharmacology (Berlin) 160, 299-306.
91. Stip E, Lussier I (1996). The effect of risperidone on cognition in patients with schizophrenia. Canadian Journal of Psychiatry 41, S35-S40.
92. Stip E, Remington GJ, Dursun SM, Reiss JP, Rotstein E, MacEwan GW, Chokka PR, Jones B, Dickson RA (2003). A Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine. Journal of Clinical Psychopharmacology 23, 400-404.
93. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A (2000). Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Archives of General Psychiatry 57, 968-976.
94. Velligan DI, Bow-Thomas CC, Mahurin RK, Miller AL, Halgunseth LC (2000). Do specific neurocognitive deficits predict specific domains of community function in schizophrenia? Journal of Nervous Disease and Mental Disorder 188, 518-524.
95. Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin R, Miller AL (2002). Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophrenia Research 53, 239-248.
96. Velligan DI, Prihoda TJ, Sui D, Ritch JL, Maples N, Miller AL (2003). The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. Journal of Clinical Psychiatry 64, 524-531.
97. Zorn SH, Jones SB, Ward KM, Liston DR (1994). Clozapine is a potent and selective muscarinic M4 receptor agonist. European Journal of Pharmacology 269, R1-R2.